Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5814.

https://doi.org/10.1182/blood-2025-5814

Published: 2025

Journal Articles

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Blood (2025) 146 (Supplement 1): 5945.

https://doi.org/10.1182/blood-2025-5945

Published: 2025

Journal Articles

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Blood (2025) 146 (Supplement 1): 804.

https://doi.org/10.1182/blood-2025-804

Published: 2025

Journal Articles

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial

Blood (2025) 146 (Supplement 1): 699.

https://doi.org/10.1182/blood-2025-699

Published: 2025

Journal Articles

Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study

Blood (2025) 146 (Supplement 1): 7189.

https://doi.org/10.1182/blood-2025-7189

Published: 2025

Journal Articles

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Blood (2025) 146 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2025-4543

Published: 2025

Journal Articles

Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma

Heta Patel, Luca Paruzzo, Oxana Megherea, Matthew Ho, Thomas Luo, Dan Vogl, Shivani Kapur, Adam Waxman, Federico Stella, Alberto Carturan, Martina Pucillo, Antonio Imparato, Edward Stadtmauer, Alfred Garfall, Adam Cohen, Marco Ruella, Sandra Susanibar-Adaniya

Blood (2025) 146 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2025-3995

Published: 2025

Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Luca Paruzzo, Khashayar Eshaghi, Guido Ghilardi, Abigail Doucette, Adam Waxman, Adam D. Cohen, Dan T. Vogl, Shivani Kapur, Eugenio Fardella, Alberto Carturan, Luke Maillie, Sofia Kaparis, Jalpa A. Doshi, Alfred L. Garfall, Edward A. Stadtmauer, Carmen E Guerra, Sandra Susanibar-Adaniya, Marco Ruella

Blood (2024) 144 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2024-206544

Published: 2024

Journal Articles

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Blood (2024) 144 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2024-206608

Published: 2024

Journal Articles

Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Dan T. Vogl, Yulia Nefedova, E. Paul Wileyto, Chau Nguyen, Cynthia Diaczynsky, Inna Strakovsky, Eva Bondesson, Helen Tuvesson, Erik Vahtola, Adam D. Cohen, Sandra Susanibar-Adaniya, Adam Waxman, Shivani Kapur, Alfred L. Garfall, Edward A. Stadtmauer

Blood (2024) 144 (Supplement 1): 7060.

https://doi.org/10.1182/blood-2024-204155

Published: 2024

Journal Articles

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Blood (2024) 144 (Supplement 1): 3381.1.

https://doi.org/10.1182/blood-2024-199411

Published: 2024

Journal Articles

Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors

Zainul S. Hasanali, Alfred L. Garfall, Dan T. Vogl, Sandra Susanibar-Adaniya, Adam D. Cohen, Edward A. Stadtmauer, Shivani Kapur, Adam Waxman, David Allman

Blood (2024) 144 (Supplement 1): 3266.

https://doi.org/10.1182/blood-2024-209100

Published: 2024

Journal Articles

Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study

Adam D. Cohen, Sandra Susanibar-Adaniya, Oksana De Mesa, Alfred L. Garfall, Dan T. Vogl, Adam Waxman, Shivani Kapur, E Paul Wileyto, Anjana Nair, Zainul S. Hasanali, Lauren Karpf, Edward A. Stadtmauer

Blood (2024) 144 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2024-203635

Published: 2024

Journal Articles

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Adam D. Cohen, Wei-Ting Hwang, Sandra Susanibar-Adaniya, Dan T. Vogl, Alfred L. Garfall, Adam Waxman, Danielle Zubka, Chau Nguyen, Cynthia Diaczynsky, Marco Ruella, Michael C. Milone, Edward A. Stadtmauer

Blood (2023) 142 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2023-187409

Published: 2023

Journal Articles

Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series

Margaret Stalker, Alfred L. Garfall, Adam D. Cohen, Dan T. Vogl, Sandra Susanibar-Adaniya, Mia Djulbegovic, Edward A. Stadtmauer, Oxana Megherea, Adam Waxman

Blood (2023) 142 (Supplement 1): 2035.

https://doi.org/10.1182/blood-2023-189277

Published: 2023

Journal Articles

A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma

Mia Djulbegovic, Meredith Doherty, Katie Fanslau, Kan Chen, Sarah Girgis, Pearl Joslyn, Shawn Carney, Joyce Mitchell, Abbie Etzweiler, Dan T. Vogl, Adam D. Cohen, Alfred L. Garfall, Adam Waxman, Sandra Susanibar-Adaniya, Zachary AK Frosch, Qi Long, Karen Glanz, Edward A. Stadtmauer

Blood (2023) 142 (Supplement 1): 909.

https://doi.org/10.1182/blood-2023-174451

Published: 2023

Journal Articles

A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Beatrice Razzo, Connor Grady, Sandra Susanibar-Adaniya, Adam Waxman, Dan T. Vogl, Adam D. Cohen, Edward A. Stadtmauer, Wei-Ting Hwang, Alfred L. Garfall

Blood (2023) 142 (Supplement 1): 3394.

https://doi.org/10.1182/blood-2023-177735

Published: 2023

Journal Articles

Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Brian Hoeynck, Wei-Ting Hwang, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer, Adam D Cohen

Blood (2022) 140 (Supplement 1): 10081–10083.

https://doi.org/10.1182/blood-2022-165650

Published: 2022

Journal Articles

Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

Adam D Cohen, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Oksana De Mesa, Elizabeth Kane, Charles Nichols, Beatrice Razzo, Edward A. Stadtmauer

Blood (2022) 140 (Supplement 1): 12628–12629.

https://doi.org/10.1182/blood-2022-165526

Published: 2022

Journal Articles

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Christopher Tor Sauter, MD, Luca L Bernabei, BA, Adam Waxman, MD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Dan T. Vogl, MD, Sara Whittington,, RN, MPH, Colleen Harker Erb, CRNP, Patricia Mangan, CRNP, Mary Sanchez, CRNP, Edward A. Stadtmauer, MD FACP

Blood (2019) 134 (Supplement_1): 5598.

https://doi.org/10.1182/blood-2019-132087

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial

Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors

Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series

A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma

A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only